These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21463186)

  • 1. Antigen/adjuvant-carrying nanoparticles show promise for vaccine delivery.
    Immunotherapy; 2011 Apr; 3(4):467. PubMed ID: 21463186
    [No Abstract]   [Full Text] [Related]  

  • 2. Phospholipid bilayer-coated aluminum nanoparticles as an effective vaccine adjuvant-delivery system.
    Wang T; Zhen Y; Ma X; Wei B; Wang N
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6391-6. PubMed ID: 25780860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
    Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
    Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticles and microparticles as vaccine-delivery systems.
    Singh M; Chakrapani A; O'Hagan D
    Expert Rev Vaccines; 2007 Oct; 6(5):797-808. PubMed ID: 17931159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
    Saul A; Lawrence G; Allworth A; Elliott S; Anderson K; Rzepczyk C; Martin LB; Taylor D; Eisen DP; Irving DO; Pye D; Crewther PE; Hodder AN; Murphy VJ; Anders RF
    Vaccine; 2005 Apr; 23(23):3076-83. PubMed ID: 15811655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers.
    Li N; Peng LH; Chen X; Nakagawa S; Gao JQ
    Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Particulate vaccines: on the quest for optimal delivery and immune response.
    De Temmerman ML; Rejman J; Demeester J; Irvine DJ; Gander B; De Smedt SC
    Drug Discov Today; 2011 Jul; 16(13-14):569-82. PubMed ID: 21570475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The path to a successful vaccine adjuvant--'the long and winding road'.
    O'Hagan DT; De Gregorio E
    Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A malaria vaccine based on a sporozoite antigen.
    Nussenzweig RS; Zavala F
    N Engl J Med; 1997 Jan; 336(2):128-30. PubMed ID: 8988893
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary characterization of N-trimethylchitosan as a nanocarrier for malaria vaccine.
    Nnamani PO; Scoles G; Kröl S
    J Vector Borne Dis; 2011 Dec; 48(4):224-30. PubMed ID: 22297285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity against Toxoplasma challenge in mice by coadministration of T. gondii antigens and Eimeria profilin-like protein as an adjuvant.
    Hedhli D; Dimier-Poisson I; Judge JW; Rosenberg B; Mévélec MN
    Vaccine; 2009 Apr; 27(16):2274-81. PubMed ID: 19428842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine.
    Wang X; Uto T; Akagi T; Akashi M; Baba M
    J Med Virol; 2008 Jan; 80(1):11-9. PubMed ID: 18041033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of adjuvant and antigen dose on protection induced by an inactivated whole vaccine against Neospora caninum infection in mice.
    Rojo-Montejo S; Collantes-Fernández E; Regidor-Cerrillo J; Rodríguez-Bertos A; Prenafeta A; Gomez-Bautista M; Ortega-Mora LM
    Vet Parasitol; 2011 Feb; 175(3-4):220-9. PubMed ID: 21067865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune enhancement of a novel soy lecithin/β-glucans based adjuvant on native Neospora caninum tachyzoite extract vaccine in mice.
    Mansilla FC; Franco-Mahecha OL; Lavoria MÁ; Moore DP; Giraldez AN; Iglesias ME; Wilda M; Capozzo AV
    Vaccine; 2012 Feb; 30(6):1124-31. PubMed ID: 22178728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immune response in toxoplasmosis after mucosal immunization with Toxoplasma gondii antigens].
    Kobets NV; Zaĭtseva LG; Goncharov DB; Gubareva EV; Mezentseva MV; Kireeva IV; Surgucheva IM; Samoĭlenko II
    Med Parazitol (Mosk); 2010; (1):10-4. PubMed ID: 20361628
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.
    Chatzikleanthous D; O'Hagan DT; Adamo R
    Mol Pharm; 2021 Aug; 18(8):2867-2888. PubMed ID: 34264684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.